Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRIMLJ)

• Drug Name: BX-795 Drug Info
• Synonyms: BX795; BX 795

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10077147
  ChEBI ID: CHEBI:91439
  CAS Number: CAS 702675-74-9
  TTD Drug ID: DMRIMLJ

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphoinositide dependent protein kinase-1 (PDPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR-12	DM4RK6P	Lymphoma	2A80-2A86	Phase 1	[3]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[4]
PMID20005102C1	DMMESBW	Discovery agent	N.A.	Investigative	[5]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[2]
PHT-427	DMI96Y3	Discovery agent	N.A.	Investigative	[6]
PF-5177624	DMUOFT0	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
GSK-2334470	DM3BI7R	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[9]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[10]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[12]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[14]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[15]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[17]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[18]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[19]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[21]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[22]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[23]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[24]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[12]

Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMO-02	DMJRU3A	Myotonic dystrophy	8C71.0	Phase 2/3	[27]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[28]
Lithium	DMZ3OU6	Fragile X syndrome	LD55	Phase 2	[29]
Tideglusib	DME4LA1	Osteosarcoma	2B51	Phase 2	[30]
9-ING-41	DM57TY3	Myelofibrosis	2A20.2	Phase 2	[31]
Neu-120	DMXKOUC	Parkinson disease	8A00.0	Phase 1/2	[32]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[33]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[34]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[35]
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[36]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[37]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[38]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[39]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[40]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[41]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[20]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[42]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[43]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[44]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[45]

Drug(s) Targeting Fungal Protein kinase A (Fung ypkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[46]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[47]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[48]
PMID20005102C1	DMMESBW	Discovery agent	N.A.	Investigative	[5]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[49]
PMID19364658C33	DMSE1C3	Discovery agent	N.A.	Investigative	[50]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[2]
Chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[51]
PMID21742770C1	DME3JMH	Discovery agent	N.A.	Investigative	[52]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)	DM1JWGH	Discovery agent	N.A.	Investigative	[53]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[2]
Fungal Protein kinase A (Fung ypkA)	TTYVI76	Q56921_YEREN	Inhibitor	[2]
Glycogen synthase kinase-3 beta (GSK-3B)	TTRSMW9	GSK3B_HUMAN	Inhibitor	[2]
Phosphoinositide dependent protein kinase-1 (PDPK1)	TT9QBI6	PDPK1_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8006).
• [2] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [5] 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
• [6] Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
• [7] Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
• [8] Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9.
• [9] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
• [10] Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
• [11] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
• [14] National Cancer Institute Drug Dictionary (drug id 730054).
• [15] Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
• [16] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [17] Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
• [18] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [19] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [20] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [21] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [22] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [23] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [24] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [25] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [26] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [27] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [28] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [29] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [30] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [31] 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
• [32] Company report (Neurim Pharmaceuticals)
• [33] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [34] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [35] Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
• [36] Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
• [37] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [38] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [40] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [41] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [42] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [43] Clinical pipeline report, company report or official report of Exelixis (2011).
• [44] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [45] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [46] Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address
• [47] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [48] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [49] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
• [50] Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
• [51] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [52] A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
• [53] Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.